An observational, open-label prospective study to evaluate the antiviral efficacy, safety, and tolerability of ombitasvir/paritaprevir/ritonavir/ribavirin in chronic kidney disease patients infected with chronic Hepatitis C infection; A real life experience
Latest Information Update: 19 Nov 2020
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 Nov 2020 New trial record
- 16 Oct 2020 Results published in the Medicine